Reduced dose and reduced exposure to non-vitamin K-antagonist oral anticoagulants: Some considerations on this relationship

被引：1
|
作者：
Rubboli, Andrea [1 ]
Verheugt, Freek W. A. [2 ]
机构：
[1] Osped Maggiore Bologna, Lab Intervent Cardiol, Div Cardiol, Largo Nigrisoli 2, I-40133 Bologna, Italy
[2] OLVG, Heartctr, Dept Cardiol, Oosterpk 9, NL-1091 AC Amsterdam, Netherlands
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2016年 / 223卷
关键词：
Non-vitamin K-antagonist oral anticoagulants; Oral anticoagulation; ATRIAL-FIBRILLATION; RENAL-FUNCTION; WARFARIN; RIVAROXABAN; DABIGATRAN; APIXABAN; EFFICACY; SAFETY;
D O I：
10.1016/j.ijcard.2016.08.207
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：519 / 520
页数：2
相关论文
共 50 条
  • [31] Non-Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease
    Al Said, Samer
    Ellscheid, Michael
    Beltsios, Eleftherios T.
    Frey, Norbert
    HAMOSTASEOLOGIE, 2022, 42 (03): : 201 - 209
  • [32] Non-vitamin K antagonist oral anticoagulants in valvular atrial fibrillation
    Basaran, Ozcan
    Dogan, Volkan
    Sahin, Cem
    Biteker, Murat
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 212 : 357 - 357
  • [33] Efficacy of non-vitamin K antagonist oral anticoagulants for Lemierre syndrome
    Kubota, Masayuki
    Daidoji, Hiroaki
    Takaya, Nobuhiro
    Tokunaga, Kurato
    Sonoo, Tomohiro
    Nakamura, Kensuke
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2016, 34 (10): : 2059.e3 - 2059.e5
  • [34] Combination of non-vitamin K antagonist oral anticoagulants and antiepileptic drugs
    Kurt, Semiha
    Sumbul, Orhan
    Aksoy, Durdane
    EUROPEAN HEART JOURNAL, 2019, 40 (19) : 1572 - 1572
  • [35] Non-vitamin K antagonist oral anticoagulants and risk of liver injury
    Douros, Antonios
    Azoulay, Laurent
    Yin, Hui
    Suissa, Samy
    Renoux, Christel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 176 - 176
  • [36] Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis
    Eiman Ghaffarpasand
    Maneli D. Tehrani
    Jolanta Marszalek
    Gerald Chi
    Journal of Thrombosis and Thrombolysis, 2018, 46 : 332 - 338
  • [37] Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
    Nielsen, Peter Bronnum
    Skjoth, Flemming
    Sogaard, Mette
    Kjaeldgaard, Jette Nordstrom
    Lip, Gregory Y. H.
    Larsen, Torben Bjerregaard
    BMJ-BRITISH MEDICAL JOURNAL, 2017, 356
  • [38] Which Patients May Benefit from Dose Adjustment of Non-Vitamin K Antagonist Oral Anticoagulants?
    Chin, Paul K. L.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2015, 41 (02): : 195 - 207
  • [39] Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease
    Mongeon, Francois-Pierre
    Macle, Laurent
    Beauchesne, Luc M.
    Bouma, Berto J.
    Schwerzmann, Markus
    Mulder, Barbara J. M.
    Khairy, Paul
    CANADIAN JOURNAL OF CARDIOLOGY, 2019, 35 (12) : 1686 - 1697
  • [40] How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?
    De Caterina, Raffaele
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2016, 18 (0I) : 1 - 6
12345